Cargando…

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

SIMPLE SUMMARY: CX-5461 is an RNA polymerase I inhibitor that is in clinical trials for both advanced hematological cancers and solid tumors. Experimentally, this drug has been shown to induce a p53-independent DNA damage response through ATM and ATR kinase, and has particular activity against chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornelison, Robert, Biswas, Kuntal, Llaneza, Danielle C., Harris, Alexandra R., Sosale, Nisha G., Lazzara, Matthew J., Landen, Charles N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533980/ https://www.ncbi.nlm.nih.gov/pubmed/34680204 http://dx.doi.org/10.3390/cancers13205056

Ejemplares similares

Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
por: Cornelison, Robert, et al.
Publicado: (2017)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461
por: Masud, Tehmina, et al.
Publicado: (2021)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
por: Son, Jinbae, et al.
Publicado: (2020)

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
por: Snyers, Luc, et al.
Publicado: (2022)

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
por: Li, Leiming, et al.
Publicado: (2016)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
por: Xu, Xia, et al.
Publicado: (2021)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020)

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
por: Negi, Sandeep S., et al.
Publicado: (2015)

The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers
por: Ismael, Mohammed, et al.
Publicado: (2019)

Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer
por: Lazo, John S., et al.
Publicado: (2021)

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis
por: Negi, Sandeep S., et al.
Publicado: (2015)

The Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases
por: Wang, Zhilei, et al.
Publicado: (2021)

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
por: Chung, Shin-Yi, et al.
Publicado: (2022)

Molecular evolutionary and structural analysis of the cytosolic DNA sensor cGAS and STING
por: Wu, Xiaomei, et al.
Publicado: (2014)

Mitochondrial damage and activation of the cytosolic DNA sensor cGAS–STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice
por: Yan, Meiling, et al.
Publicado: (2022)

Cytosolic DNA sensing through cGAS and STING is inactivated by gene mutations in pangolins
por: Fischer, Heinz, et al.
Publicado: (2020)

Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor
por: McQueeney, Kelley E., et al.
Publicado: (2017)

Macrophage Cx43 Is Necessary for Fibroblast Cytosolic Calcium and Lung Fibrosis After Injury
por: Bhattacharyya, Aritra, et al.
Publicado: (2022)

STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression
por: Le Bert, Nina, et al.
Publicado: (2014)

Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway
por: Zhang, Jing, et al.
Publicado: (2023)

Cytosolic DNA‐STING‐NLRP3 axis is involved in murine acute lung injury induced by lipopolysaccharide
por: Ning, Li, et al.
Publicado: (2020)

Tissue fluidification promotes a cGAS–STING cytosolic DNA response in invasive breast cancer
por: Frittoli, Emanuela, et al.
Publicado: (2022)

Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis
por: Hu, Qiongyuan, et al.
Publicado: (2021)

Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
por: Zheng, Huan, et al.
Publicado: (2022)

Inhibition of Tumor‐induced Angiogenesis by a Synthetic Lipid A Analogue with Low Endotoxicity, DT‐5461
por: Sato, Katsuaki, et al.
Publicado: (1995)

cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells
por: Suter, Manuel Adrian, et al.
Publicado: (2021)

IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation
por: Xiong, Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q58hmpdotjrpiq02m1m6ginjk8